SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is closing out 2025 on fresh clinical data, a major late-stage catalyst approaching..
SELLAS just presented updated Phase 2 AML data for SLS009 at ASH 2025, while its Phase 3 REGAL trial of galinpepimut-S (GPS) is event-driven and management has said the final analysis is anticipated by year-end 2025
SELLAS is a late-stage clinical biopharmaceutical company developing oncology therapeutics. Its pipeline is currently centered on two key programs:Galinpepimut-S (GPS), an immunotherapy targeting WT1 (Wilms tumor 1) SLS009, a CDK9 inhibitor (cyclin-dependent kinase 9)
On Dec. 7, 2025, when SELLAS reported Phase 2 expansion data for SLS009 in combination with azacitidine (AZA) and venetoclax (VEN) in relapsed/refractory AML with myelodysplastic syndrome-related changes (AML-MR) after prior venetoclax-based therapy, presented at ASH 2025.
On Dec. 7, 2025, when SELLAS reported Phase 2 expansion data for SLS009 in combination with azacitidine (AZA) and venetoclax (VEN) in relapsed/refractory AML with myelodysplastic syndrome-related changes (AML-MR) after prior venetoclax-based therapy, presented at ASH 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.